What is HC Wainwright’s Estimate for BLSM Q3 Earnings?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) – Analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of BlossomHill Therapeutics in a note issued to investors on Thursday, September 24th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.93) per share for the quarter, down from their prior forecast of ($0.92). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for BlossomHill Therapeutics’ current full-year earnings is ($5.54) per share. HC Wainwright also issued estimates for BlossomHill Therapeutics’ Q4 2026 earnings at ($0.92) EPS and FY2026 earnings at ($4.75) EPS.

BlossomHill Therapeutics (NASDAQ:BLSM) last released its quarterly earnings data on Friday, September 18th. The company reported ($8.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91).

Several other brokerages also recently commented on BLSM. Leerink Partners raised their price target on shares of BlossomHill Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, September 21st. Wall Street Zen upgraded BlossomHill Therapeutics to a “hold” rating in a research report on Saturday, August 15th. Lifesci Capital began coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set an “outperform” rating and a $32.00 price objective for the company. Zacks Research raised BlossomHill Therapeutics to a “hold” rating in a research note on Wednesday, September 2nd. Finally, JPMorgan Chase & Co. started coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.00.

BlossomHill Therapeutics Stock Up 8.1%

BlossomHill Therapeutics stock opened at $21.34 on Monday. BlossomHill Therapeutics has a 1-year low of $15.25 and a 1-year high of $27.99.

Insider Transactions at BlossomHill Therapeutics

In related news, Director John P. Schmid acquired 6,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of $16.00 per share, with a total value of $96,000.00. Following the acquisition, the director owned 6,000 shares of the company’s stock, valued at approximately $96,000. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bihua Chen bought 312,500 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the completion of the transaction, the director directly owned 3,614,034 shares of the company’s stock, valued at $57,824,544. This represents a 9.47% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.